Government of Canada
Symbol of the Government of Canada


Vol. 144, No. 29 — July 17, 2010

COMMISSIONS

CANADA REVENUE AGENCY

INCOME TAX ACT

Revocation of registration of a charity

The following notice of proposed revocation was sent to the charity listed below revoking it for failure to meet the parts of the Income Tax Act as listed in this notice:

“Notice is hereby given, pursuant to paragraphs 168(1)(b) and 168(1)(e) of the Income Tax Act, that I propose to revoke the registration of the organization listed below and that the revocation of the registration is effective on the date of publication of this notice.”

Business Number

Name/Address

865677967RR0001

KOREAN FEDERATION OF CANADA MISSIONS SOCIETY, SURREY, B.C.

CATHY HAWARA
Acting Director General
Charities Directorate

[29-1-o]

CANADA REVENUE AGENCY

INCOME TAX ACT

Revocation of registration of a charity

The following notice of proposed revocation was sent to the charity listed below revoking it for failure to meet the parts of the Income Tax Act as listed in this notice:

“Notice is hereby given, pursuant to paragraphs 168(1)(b), 168(1)(d) and 168(1)(e) of the Income Tax Act, that I propose to revoke the registration of the organization listed below and that the revocation of the registration is effective on the date of publication of this notice.”

Business Number

Name/Address

119208494RR0001

TAMIL (SRI LANKA) REFUGEE-AID SOCIETY OF OTTAWA, OTTAWA, ONT.

CATHY HAWARA
Acting Director General
Charities Directorate

[29-1-o]

CANADA REVENUE AGENCY

INCOME TAX ACT

Revocation of registration of charities

Following a request from the charities listed below to have their status as a charity revoked, the following notice of intention to revoke was sent:

“Notice is hereby given, pursuant to paragraph 168(1)(a) of the Income Tax Act, that I propose to revoke the registration of the charities listed below and that by virtue of paragraph 168(2)(a) thereof, the revocation of the registration is effective on the date of publication of this notice in the Canada Gazette.”

Business Number

Name/Address

107981516RR0001

SIMCOE OUTREACH SERVICES INC., BARRIE, ONT.

118787142RR0057

ALL SAINTS CHURCH, CROFTON, B.C.

118800986RR0001

BAYVIEW FAIRWAYS SCHOOL COUNCIL, THORNHILL, ONT.

118814425RR0001

BOYLSTON BAPTIST CHURCH, BOYLSTON, N.S.

118912062RR0001

FAITH LUTHERAN CHURCH, PROVOST, ALTA.

118970482RR0001

INTERNATIONAL CHURCH OF THE GOLDEN KEYS AND CHRISTIAN SCHOOL OF MENTAL SCIENCE SOCIETY, LARRY’S RIVER, N.S.

118983170RR0001

KISBEY AND DISTRICT DONORS CHOICE APPEAL, KISBEY, SASK.

119055515RR0001

NEW HORIZONS VILLAGE CRAFTS SOCIETY, VICTORIA, B.C.

119063469RR0001

NOVA SCOTIA HOSPITAL FOUNDATION, DARTMOUTH, N.S.

119092740RR0001

PHYSICALLY HANDICAPPED INDEPENDENT ADVANCEMENT COMMUNITY SERVICES, TORONTO, ONT.

119098713RR0001

PRESBYTERIAN WOMENS MISSIONARY SOCIETY, WESTERN DIVISION, WHALLEY PRESBYTERIAN CHURCH EVENING GUILD (AFFILIATED WITH WHALLEY PRESBYTERIAN CHURCH), SURREY, B.C.

119118560RR0001

RICHARD GORDON UTAS MEMORIAL TRUST, EDMONTON, ALTA.

119145258RR0001

SENIOR CITIZENS SPECIAL SERVICES SOCIETY OF WEST VANCOUVER, WEST VANCOUVER, B.C.

119264984RR0001

TIMMINS VOLUNTEER CENTRE INC., TIMMINS, ONT.

119289114RR0001

WATERLOO MATHEMATICS FOUNDATION, WATERLOO, ONT.

128325958RR0001

SOCIÉTÉ DE PROMOTION DE GESTION AGRICOLE DU QUÉBEC INC., SAINT-JACQUES (QC)

130025877RR0001

VICTORIA RIGHT TO LIFE SOCIETY, VICTORIA, B.C.

130387665RR0017

SPONSORING COMMITTEE OF NO. 618 (QUEEN CITY) SQUADRON, ROYAL CANADIAN, AIR CADETS, TORONTO, ONT.

131044356RR0001

KELOWNA DROP-IN AND INFORMATION CENTRE, KELOWNA, B.C.

131629958RR0001

ST. MATTHEW LUTHERAN CHURCH, STRATFORD, ONT.

132331547RR0001

C.D. COMMUNITY CHURCH (CASTLE DOWNS), EDMONTON, ALTA.

133522011RR0001

NORTHWEST CENTRE FOR WORLD MISSION, VANCOUVER, B.C.

135038628RR0001

CENTRE D’ANIMATION MULTI ETHNIQUE ÉDUCATIF ROSEMONT (C.A.M.E.R.), MONTRÉAL (QC)

135323772RR0001

HURON UNITED WAY, STRATFORD, ONT.

807036298RR0001

JAH-JIREH SENIORS SOCIETY OF ALBERTA, RED DEER, ALTA.

812895944RR0001

JUNK TO JOY, ALTONA, MAN.

814211074RR0001

HABITATION L’ENVOLÉE DE BEAUCE, SAINT-GEORGES-DE-BEAUCE (QC)

814661146RR0001

FRIENDS OF HOPE’S HOME, REGINA, SASK.

834922015RR0001

TAXQ FOUNDATION, MISSISSAUGA, ONT.

836103226RR0001

RIVER OF LIFE CHURCH, COQUITLAM, B.C.

836486928RR0001

FONDATION MAISON DE RÊVES, SAINT-LAMBERT (QC)

848174553RR0001

CAFÉ LUMIERA, MONTRÉAL (QC)

849468921RR0001

HEAVEN’S LITTLE ANGELS FOUNDATION INC., WINNIPEG, MAN.

849572755RR0001

DEVON COMMUNITY BEFORE AND AFTER SCHOOL CARE, DEVON, ALTA.

862706769RR0001

BARRIER ELIMINATION ACTION CORP., TIMMINS, ONT.

862996097RR0001

EMBRACING CHILDREN HUMANITARIAN ORGANIZATION, VICTORIA, B.C.

863472940RR0001

CANADIAN HORSE AND PONY PROTECTION ASSOCIATION, BARRIE, ONT.

869753822RR0001

WAINWRIGHT - THE WAY OF THE WEST PROMOTION SOCIETY, WAINWRIGHT, ALTA.

869884643RR0001

CHARTWELL INSTITUTE FOR CARE AND COUNSELLING, OAKVILLE, ONT.

870905338RR0001

COFFIN ISLAND LIGHTHOUSE HERITAGE SOCIETY, QUEENS COUNTY, N.S.

870964673RR0001

FIRST NATIONS BAPTIST CHURCH, SASKATOON, SASK.

871460937RR0001

RESTORATION COUNSELLING AND COMMUNITY SERVICES, NORTH YORK, ONT.

873395578RR0001

COUNSEL CARE FOUNDATION, TORONTO, ONT.

874005366RR0001

CHURCH OF DIVINE LOVE, SURREY, B.C.

875248957RR0001

NON-PROFIT MOBILE SERVICE CORPORATION OF FORT ERIE, FORT ERIE, ONT.

879059517RR0001

ABBOTSFORD MENNONITE FELLOWSHIP, ABBOTSFORD, B.C.

883963407RR0001

FIRST REVIVAL PENTECOSTAL CHURCH, BELLEDUNE, N.B.

885382119RR0001

D. BLEASDELL BOULDER PRESERVATION CORPORATION, GLEN MILLER, ONT.

887847861RR0001

CHIU UY MEMORIAL FOUNDATION, RICHMOND, B.C.

888066065RR0001

ST. MICHAEL AND ALL ANGELS ANGLICAN CHURCH, KISBEY, SASKATCHEWAN, KISBEY, SASK.

888383833RR0001

THE LIGHT OF THE COUNTRY GOSPEL CHURCH, BRAMPTON, ONT.

888863669RR0001

SPIRITUAL TEMPLE OF LIGHT SOCIETY, BURNABY, B.C.

888899069RR0001

THE HARTFORD WELLINGTON VILLAGE HALL SOCIETY, WELLINGTON, N.S.

889154241RR0001

KILLARNEY PARK FRIENDSHIP SOCIETY, VANCOUVER, B.C.

889608378RR0001

LA CHAPELLE DU SACRÉ-CŒUR, MESSINES (QC)

889665196RR0001

DRAYTON CALVIN CHRISTIAN SCHOOL FOUNDATION, MOOREFIELD, ONT.

890037229RR0001

FONDATION T.T. BELZ/T.T. BELZ FOUNDATION, OUTREMONT (QC)

890240377RR0001

NORTH ADDINGTON EDUCATION CENTRE COMMUNITY SCHOOL COUNCIL, CLOYNE, ONT.

890811540RR0001

BRITISH COLUMBIA ASSOCIATION OF COVENANTING CONGREGATIONS, RICHMOND, B.C.

890948243RR0001

ROSSEAU LAKE COLLEGE FOUNDATION, ROSSEAU, ONT.

891078586RR0001

WOMEN’S MISSIONARY SOCIETY, ST. ANDREW’S PRESBYTERIAN CHURCH, PENTICTON, B.C., PENTICTON, B.C.

891548547RR0001

COMITÉ DES ŒUVRES CHARITABLES DU CONSEIL STE-TRINITÉ DE GRANBY 9842-05, GRANBY (QC)

891578940RR0001

COMITÉ DES ŒUVRES CHARITABLES DU CONSEIL DUPARQUET 3107, DUPARQUET (QC)

891693442RR0001

SECTION CANADIENNE DU CONSEIL INTERNATIONAL DES ÉGLISES COMMUNAUTAIRES/ CANADIAN CHAPTER OF THE INTERNATIONAL COUNCIL OF COMMUNITY CHURCHES, OTTAWA (ONT.)

892505454RR0001

FONDATION GROUPE FLEURBEC, LÉVIS (QC)

892648643RR0001

THE CARL AND PHOEBE CONWAY FAMILY FOUNDATION, TORONTO, ONT.

892912643RR0001

SHE’ARIM PARENTS LEAGUE, TORONTO, ONT.

894538628RR0001

DICKINSFIELD COMMUNITY PARTNERSHIP SOCIETY, EDMONTON, ALTA.

895686616RR0001

SMART GROWTH BRITISH COLUMBIA, VANCOUVER, B.C.

CATHY HAWARA
Acting Director General
Charities Directorate

[29-1-o]

CANADIAN INTERNATIONAL TRADE TRIBUNAL

DECISION

Appeal No. AP-2009-003

Notice is hereby given that the Canadian International Trade Tribunal made a decision on July 2, 2010, with respect to an appeal filed by CapsCanada® Corporation from a decision of the President of the Canada Border Services Agency dated January 26, 2009, with respect to a request for re-determination pursuant to subsection 60(4) of the Customs Act.

The appeal, heard on April 20, 2010, pursuant to subsection 67(1) of the Customs Act, was dismissed.

Further information may be obtained from the Secretary, Canadian International Trade Tribunal, Standard Life Centre, 15th Floor, 333 Laurier Avenue W, Ottawa, Ontario K1A 0G7, 613-993-3595 (telephone), 613-990-2439 (fax), secretary@citt-tcce.gc.ca (email).

Ottawa, July 5, 2010

DOMINIQUE LAPORTE
Secretary

[29-1-o]

CANADIAN INTERNATIONAL TRADE TRIBUNAL

DECISION

Appeal No. AP-2009-007

Notice is hereby given that the Canadian International Trade Tribunal made a decision on July 8, 2010, with respect to an appeal filed by Sanus Systems from a decision of the President of the Canada Border Services Agency dated February 6, 2009, with respect to a request for re-determination pursuant to subsection 60(4) of the Customs Act.

The appeal, heard on June 2, 2010, pursuant to subsection 67(1) of the Customs Act, was allowed.

Further information may be obtained from the Secretary, Canadian International Trade Tribunal, Standard Life Centre, 15th Floor, 333 Laurier Avenue W, Ottawa, Ontario K1A 0G7, 613-993-3595 (telephone), 613-990-2439 (fax), secretary@citttcce.gc.ca (email).

Ottawa, July 8, 2010

DOMINIQUE LAPORTE
Secretary

[29-1-o]

CANADIAN INTERNATIONAL TRADE TRIBUNAL

DECISION

Appeal No. AP-2009-056

Notice is hereby given that the Canadian International Trade Tribunal made a decision on July 8, 2010, with respect to an appeal filed by Future Product Sales Inc. from a decision of the President of the Canada Border Services Agency dated July 22, 2009, with respect to a request for re-determination pursuant to subsection 60(4) of the Customs Act.

The appeal, heard on May 6, 2010, pursuant to subsection 67(1) of the Customs Act, was allowed.

Further information may be obtained from the Secretary, Canadian International Trade Tribunal, Standard Life Centre, 15th Floor, 333 Laurier Avenue W, Ottawa, Ontario K1A 0G7, 613-993-3595 (telephone), 613-990-2439 (fax), secretary@citt-tcce.gc.ca (email).

Ottawa, July 8, 2010

DOMINIQUE LAPORTE
Secretary

[29-1-o]

CANADIAN RADIO-TELEVISION AND TELECOMMUNICATIONS COMMISSION

NOTICE TO INTERESTED PARTIES

The following notices are abridged versions of the Commission’s original notices bearing the same number. The original notices contain a more detailed outline of the applications, including additional locations and addresses where the complete files may be examined. The relevant material, including the notices and applications, is available for viewing during normal business hours at the following offices of the Commission:

— Central Building, Les Terrasses de la Chaudière, Room 206, 1 Promenade du Portage, Gatineau, Quebec K1A 0N2, 819-997-2429 (telephone), 994-0423 (TDD), 819-994-0218 (fax);

— Metropolitan Place, Suite 1410, 99 Wyse Road, Dartmouth, Nova Scotia B3A 4S5, 902-426-7997 (telephone), 426-6997 (TDD), 902-426-2721 (fax);

— Kensington Building, Suite 1810, 275 Portage Avenue, Winnipeg, Manitoba R3B 2B3, 204-983-6306 (telephone), 983-8274 (TDD), 204-983-6317 (fax);

— 530–580 Hornby Street, Vancouver, British Columbia V6C 3B6, 604-666-2111 (telephone), 666-0778 (TDD), 604-666-8322 (fax);

— CRTC Documentation Centre, 205 Viger Avenue W, Suite 504, Montréal, Quebec H2Z 1G2, 514-283-6607 (telephone), 283-8316 (TDD), 514-283-3689 (fax);

— CRTC Documentation Centre, 55 St. Clair Avenue E, Suite 624, Toronto, Ontario M4T 1M2, 416-952-9096 (telephone), 416-954-6343 (fax);

— CRTC Documentation Centre, Cornwall Professional Building, Room 103, 2125 11th Avenue, Regina, Saskatchewan S4P 3X3, 306-780-3422 (telephone), 306-780-3319 (fax);

— CRTC Documentation Centre, 10405 Jasper Avenue, Suite 520, Edmonton, Alberta T5J 3N4, 780-495-3224 (telephone), 780-495-3214 (fax).

Interventions must be filed with the Secretary General, Canadian Radio-television and Telecommunications Commission, Ottawa, Ontario K1A 0N2, together with proof that a true copy of the intervention has been served upon the applicant, on or before the deadline given in the notice.

Secretary General

CANADIAN RADIO-TELEVISION AND TELECOMMUNICATIONS COMMISSION

DECISIONS

The complete texts of the decisions summarized below are available from the offices of the CRTC.

2010-418 June 30, 2010

Golden West Broadcasting Ltd.
Winnipeg, Manitoba

Approved — Renewal of the broadcasting licence for the English-language specialty radio station CFEQ-FM Winnipeg, from July 1, 2010, to August 31, 2013.

2010-419 June 30, 2010

Lighthouse Broadcasting Limited
Medicine Hat, Alberta

Approved — Renewal of the broadcasting licence for the English-language specialty radio station CJLT-FM Medicine Hat, from July 1, 2010, to August 31, 2013.

2010-420 June 30, 2010

Vista Radio Ltd.
Prince George, British Columbia

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CJCI-FM Prince George, from July 1, 2010, to August 31, 2013.

2010-421 June 30, 2010

663975 B.C. Ltd.
Fort St. John, British Columbia

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKFU-FM Fort St. John, from July 1, 2010, to August 31, 2013.

Denied — Exception to the requirement to devote at least 60% of the basic annual Canadian content development contribution to FACTOR or MUSICACTION.

2010-422 June 30, 2010

Touch Canada Broadcasting (2006) Inc. (the general partner), and Touch Canada Broadcasting Inc. (the limited partner), carrying on business as Touch Canada Broadcasting Limited Partnership
Calgary, Alberta

Approved — Renewal of the broadcasting licence for the English-language specialty radio station CJSI-FM Calgary, from July 1, 2010, to August 31, 2013.

2010-423 June 30, 2010

JOCO Communications Inc.
Sturgeon Falls, Ontario

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CFSF-FM Sturgeon Falls, from July 1, 2010, to August 31, 2013.

2010-424 June 30, 2010

Battlefords Tourism & Convention Association Inc.
North Battleford, Saskatchewan

Approved — Renewal of the broadcasting licence for the low-power, English-language tourist information radio station CHBT-FM North Battleford, from July 1, 2010, to August 31, 2013.

2010-425 June 30, 2010

The Haliburton Broadcasting Group Inc.
Cochrane, Ontario

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHPB-FM Cochrane, from July 1, 2010, to August 31, 2013.

2010-426 June 30, 2010

Mennonite Community Services of Southern Ontario
Aylmer, Ontario

Approved — Renewal of the broadcasting licence for the ethnic commercial radio station CHPD-FM Aylmer, from July 1, 2010, to August 31, 2013.

Denied — Amendment to a condition of licence relating to the language of broadcast so that the station may broadcast in languages other than German.

2010-427 June 30, 2010

Rogers Broadcasting Limited
Ottawa, Ontario

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CISS-FM Ottawa, from July 1, 2010, to August 31, 2013.

2010-428 June 30, 2010

Canadian Hellenic Cable Radio Ltd.
Montréal, Quebec

Approved — Renewal of the broadcasting licence for the commercial ethnic FM radio station CKDG-FM Montréal, from July 1, 2010, to August 31, 2013.

2010-429 June 30, 2010

Radio CJFP (1986) ltée
Trois-Pistoles, Quebec

Approved — Renewal of the broadcasting licence for the French-language commercial radio station CIEL-FM-4 Trois-Pistoles, from July 1, 2010, to August 31, 2013.

2010-430 June 30, 2010

Radio Témiscamingue incorporée
Ville-Marie and Témiscaming, Quebec

Approved — Renewal of the broadcasting licence for the French-language commercial radio station CKVM-FM Ville-Marie and its transmitter CKVM-FM-1 Témiscaming, from July 1, 2010, to August 31, 2013.

2010-431 June 30, 2010

Radio du Golfe inc.
Sainte-Anne-des-Monts, La Martre, Mont-Louis, Les Méchins, Grande-Vallée, Gros-Morne, Cloridorme and Murdochville, Quebec

Approved — Renewal of the broadcasting licence for the French-language commercial radio station CJMC-FM Sainte-Anne-des-Monts and its transmitters, from July 1, 2010, to August 31, 2013.

2010-432 June 30, 2010

9174-8004 Québec inc.
Sainte-Marie de Beauce, Quebec

Approved — Renewal of the broadcasting licence for the French-language commercial radio station CHEQ-FM Sainte-Marie de Beauce, from July 1, 2010, to August 31, 2013.

2010-433 June 30, 2010

Jim Pattison Broadcast Group Ltd. (the general partner) and Jim Pattison Industries Ltd. (the limited partner), carrying on business as Jim Pattison Broadcast Group Limited Partnership
Prince George and Mackenzie, British Columbia

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKDV-FM Prince George and its transmitter CKMK Mackenzie, from July 1, 2010, to August 31, 2013.

2010-434 June 30, 2010

Hope FM Ministries Limited
Truro, Nova Scotia

Approved — Renewal of the broadcasting licence for the English-language specialty radio station CINU-FM Truro, from July 1, 2010, to August 31, 2013.

2010-435 June 30, 2010

CHFN Communications Society
Cape Croker (Neyaashiinigmiing), Ontario

Approved — Renewal of the broadcasting licence for the Native English- and Ojibway-language Type B radio station CHFN-FM Cape Croker, from July 1, 2010, to August 31, 2013.

2010-436 June 30, 2010

Newfoundland Broadcasting Company Limited
St. John’s, Argentia, Rattling Brook, Stephenville, Marystown, Elliston, Corner Brook, Red Rocks and Clarenville, Newfoundland and Labrador

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHOZ-FM St. John’s and its transmitters, from July 1, 2010, to August 31, 2013.

2010-437 June 30, 2010

CIAM Media & Radio Broadcasting Association
Charlie Lake and Vanderhoof, British Columbia

Fort Vermilion, Red Earth, Buffalo Head, Watt Mountain, Foggy Mountain, Weberville, Hines Creek, Slave Lake, Cleardale, Peerless Lake, Wabasca, Fort Chipewyan, Meander River, Chateh and Manning, Alberta

Buckland, Saskatchewan

Approved — Renewal of the broadcasting licence for the low-power, English-language Type B community radio programming undertaking CIAM-FM Fort Vermilion and its transmitters, from July 1, 2010, to August 31, 2013.

2010-438 June 30, 2010

Harvard Broadcasting Inc.
Regina, Saskatchewan

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKRM Regina, from July 1, 2010, to August 31, 2013.

2010-439 June 30, 2010

Harvard Broadcasting Inc.
Regina, Saskatchewan

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHMX-FM Regina, from July 1, 2010, to August 31, 2013.

2010-440 June 30, 2010

3885275 Canada Inc.
Toronto, Ontario

Approved — Renewal of the broadcasting licence for the commercial ethnic radio programming undertaking CJSA-FM Toronto, from July 1, 2010, to August 31, 2013.

2010-441 June 30, 2010

Sound of Faith Broadcasting
Kitchener-Waterloo, Ontario

Approved — Renewal of the broadcasting licence for the English-language specialty radio station CJTW-FM Kitchener, from July 1, 2010, to August 31, 2013.

2010-442 June 30, 2010

Raedio Inc.
Stratford, Ontario

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHGK-FM Stratford, from July 1, 2010, to August 31, 2013.

2010-443 June 30, 2010

United Christian Broadcasters Canada
Belleville, Cobourg, Brockville, Kingston and Bancroft, Ontario

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKJJ-FM Belleville and its transmitters, from July 1, 2010, to August 31, 2013.

2010-444 June 30, 2010

Coast Broadcasting Ltd.
St. John’s, Newfoundland and Labrador

Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKSJ-FM St. John’s, from July 1, 2010, to August 31, 2013.

2010-457 July 6, 2010

La radio communautaire de LaSalle
Montréal (LaSalle Borough), Quebec

Approved — Application to change the authorized contours of the French-language Type B community radio station CKVL-FM Montréal (LaSalle Borough).

2010-458 July 6, 2010

Salt Spring Island Radio Corporation
Salt Spring Island, British Columbia

Approved — Application to change the authorized contours of the English-language commercial radio station CFSI-FM Salt Spring Island.

2010-459 July 6, 2010

Pelmorex Communications Inc.
Across Canada

Approved — Amendment to the broadcasting licence for the weather information specialty service known as The Weather Network/MétéoMédia in order to allow it to be made available for distribution in high-definition format.

2010-463 July 8, 2010

Corus Radio Company
Brampton, Ontario

The Commission finds that CFNY-FM Brampton’s broadcast of The Dean Blundell Show on March 20, 2009, did not fail to meet the objective of the Broadcasting Act that programming be of a high standard.

2010-465 July 9, 2010

Rogers Broadcasting Limited
Moncton and Saint John, New Brunswick

Approved — Applications to amend the broadcasting licences for the news/talk commercial radio stations CKNI-FM Moncton and CHNI-FM Saint John by changing the condition of licence that limits the amount of music they may broadcast.

2010-466 July 9, 2010

Rogers Broadcasting Limited
Across Canada

Approved — Application to amend the broadcasting licence for the national, English-language specialty television service known as Outdoor Life Network in order to add certain program categories to the list of program categories that may be broadcast by the service and to increase the amount of programming that may be drawn from category 7, Drama and comedy, as a whole.

Denied — Request to amend the requirements that all programming drawn from category 7 be Canadian and that programming from category 6(a), Professional sports, not include stick and ball sports.

2010-467 July 9, 2010

TVA Group Inc.
Sherbrooke, Quebec

Approved — Application to amend the broadcasting licence for CHLT-TV Sherbrooke in order to add a digital transmitter.

[29-1-o]

CANADIAN RADIO-TELEVISION AND TELECOMMUNICATIONS COMMISSION

NOTICE OF CONSULTATION 2010-454

Notice of applications received

Various locations
Deadline for submission of interventions and/or comments: August 6, 2010

The Commission has received the following applications:

1. FDR Media Group Inc.
Across Canada

To amend the broadcasting licence for the national, third-language ethnic Category 2 specialty service known as Bollywood Times HD TV, approved in Broadcasting Decision 2010-268.

2. FDR Media Group Inc.
Across Canada

To amend the broadcasting licence for the national, third-language ethnic Category 2 specialty service known as Mehndi HD TV, approved in Broadcasting Decision 2010-270.

3. Canadian Broadcasting Corporation
Montréal, Quebec

To modify the technical parameters of CBF-FM Montréal’s rebroadcasting transmitter CBF-FM-20 Saint-Donat.

4. Canadian Broadcasting Corporation
Trois-Rivières, Quebec

To amend the broadcasting licences for the French-language FM radio stations CBF-FM-8 Trois-Rivières and CBF-FM Montréal by transferring the transmitters CBF-16 Clova, CBF-17 Lac Édouard and CBF-18 Parent from CBF-FM to CBF-FM-8.

5. Canadian Broadcasting Corporation
Ottawa, Ontario

To amend the broadcasting licence for the English-language radio station CBO-FM Ottawa by changing the frequency of the rebroadcasting transmitter CBOB-FM Brockville.

July 5, 2010

[29-1-o]

CANADIAN RADIO-TELEVISION AND TELECOMMUNICATIONS COMMISSION

NOTICE OF CONSULTATION 2010-464

Notice of applications received

Various locations Deadline for submission of interventions and/or comments: August 12, 2010

The Commission has received the following applications:

1. TVA Group Inc.
Québec, Quebec

To amend the broadcasting licence for the French-language television station CFCM-TV Québec in order to add a digital transmitter at Québec to broadcast the programming of CFCM-TV, in the digital format.

2. 1486781 Ontario Limited
Brantford, Ontario

To effect a change to the effective control of 1486781 Ontario Limited through the transfer of all of its issued and outstanding shares from its sole shareholder, Anthony Schleifer, to Durham Radio Inc., pursuant to subsection 11(4) of the Radio Regulations, 1986.

3. 1486781 Ontario Limited
Brantford, Ontario

To amend the broadcasting licence for the English-language specialty FM radio station CFWC-FM Brantford in order to delete conditions of licence relating to the broadcast of musical selections and in order to offer a broad-based rock format.

July 8, 2010

[29-1-o]

CANADIAN RADIO-TELEVISION AND TELECOMMUNICATIONS COMMISSION

NOTICE OF CONSULTATION 2010-468

Notice of application received

Halifax and Sydney, Nova Scotia; Moncton and Saint John, New Brunswick; Montréal, Quebec; Ottawa, Toronto, Kitchener, Sudbury, Timmins, North Bay and Sault Ste. Marie, Ontario; Winnipeg, Manitoba; Saskatoon, Regina, Prince Albert and Yorkton, Saskatchewan; Calgary, Lethbridge and Edmonton, Alberta; and Vancouver, British Columbia

Deadline for submission of interventions and/or comments: August 13, 2010

The Commission has received the following application:

1. CTVglobemedia Inc., on behalf of its wholly owned subsidiary CTV Television Inc.
Halifax and Sydney, Nova Scotia; Moncton and Saint John, New Brunswick; Montréal, Quebec; Ottawa, Toronto, Kitchener, Sudbury, Timmins, North Bay and Sault Ste. Marie, Ontario; Winnipeg, Manitoba; Saskatoon, Regina, Prince Albert and Yorkton, Saskatchewan; Calgary, Lethbridge and Edmonton, Alberta; and Vancouver, British Columbia

To amend the broadcasting licences for various television stations in regard to the broadcast of Canadian programs.

July 9, 2010

[29-1-o]

INTERNATIONAL JOINT COMMISSION

BOUNDARY WATERS TREATY OF 1909

Review of the bi-national management of the Lake of the Woods and Rainy River Basin

By letters dated June 17, 2010, the governments of Canada and the United States asked the International Joint Commission (IJC) to examine and make recommendations regarding the bi-national management of the Lake of the Woods and Rainy River Basin system and the IJC’s potential role in this management.

This review would serve to complement government activities that foster trans-jurisdictional coordination and collaboration on science and management activities to enhance and restore water quality in the basin. It would also contribute to any future approach to addressing new and emerging water quality issues and water management needs. A final report is expected to be released by the end of 2011. In the meantime, the IJC will make periodic reports to the governments that will include plans for engaging with federal governments and relevant provinces, First Nations, tribes and states, as well as the wider body of stakeholders and the public. The IJC anticipates holding public consultations on this matter at dates and locations to be announced in the local news media and on the IJC’s Web site.

In addition to the public hearings, the IJC invites all interested parties to submit written comments over the course of this review to the addresses below:

Secretary, Canadian Section
234 Laurier Avenue W
22nd Floor
Ottawa, Ontario K1P 6K6
Fax: 613-993-5583
Email: Commission@ottawa.ijc.org

Secretary, United States Section
2000 L Street, Suite 615
Washington, DC 20440
Fax: 202-632-2007
Email: Commission@washington.ijc.org

The International Joint Commission is a bi-national Canada–United-States organization established by the Boundary Waters Treaty of 1909. It assists the governments in managing waters along the border for the benefit of both countries in a variety of ways including examining issues referred to it by the two federal governments.

More information, including the full text of the governments’ letters of reference, may be found on the Commission’s Web site, at www.ijc.org.

[29-1-o]

PATENTED MEDICINE PRICES REVIEW BOARD

NOTICE AND COMMENT ISSUED BY THE PATENTED MEDICINE PRICES REVIEW BOARD ON JUNE 18, 2010, FOR FASLODEX®

TAKE NOTICE that the Vice-Chairperson of the Patented Medicine Prices Review Board (“Board” or “PMPRB”) proposes to accept a Voluntary Compliance Undertaking (VCU) in respect of the price of the medicine FASLODEX. AND TAKE NOTICE that written submissions in respect of the proposed Voluntary Compliance Undertaking will be considered.

A. Purpose of this Notice

1. The purpose of this Notice is to provide Ministers of Health in the provinces and territories of Canada and other interested persons with an opportunity to make submissions on the appropriateness of accepting a Voluntary Compliance Undertaking in the form set out in Attachment 1 with respect to the price proposed by AstraZeneca Canada Inc. (“AstraZeneca”) for the patented medicine FASLODEX®.

B. Background

2. FASLODEX is indicated for the hormonal treatment of locally advanced or metastatic breast cancer in po.3st-menopausal women, regardless of age, who have disease progression following prior endocrine therapy. It is supplied in a pre-filled syringe in a strength of 50 mg/mL and is administered at monthly intervals as a single 5 mL intramuscular injection.

3. Canadian Patent No. 2,351,004 pertaining to FASLODEX was granted to AstraZeneca AB, Sweden on February 18, 2003 and will expire on January 8, 2021. AstraZeneca is the patentee for the purposes of the PMPRB.

4. Health Canada issued a Notice of Compliance (NOC) to AstraZeneca for FASLODEX on February 17, 2004 (DIN 02248624). FASLODEX was first sold in Canada on February 1, 2006.

5. Pursuant to sub-section 85 (1) of the Patent Act (Act), and for purposes of determining whether the price of a patented medicine is excessive under section 83, the Board shall take into consideration the following factors, to the extent that information on such factors is available to the Board:

a. the prices at which the medicine has been sold in the relevant market;

b. the prices at which other medicines in the same therapeutic class have been sold in the relevant market;

c. the prices at which the medicine and other medicines in the same therapeutic class have been sold in countries other than Canada;

d. changes in the Consumer Price Index; and

e. such other factors as may be specified in any regulations made for the purposes of this subsection.

6. Based on the Board’s previous Excessive Price Guidelines (pre-2010 Guidelines), the Human Drug Advisory Panel (HDAP) recommended that FASLODEX pre-filled syringes be classified as a category 3 new drug product (provides moderate, little or no therapeutic advantage over comparable existing drug products). The HDAP also identified the oral therapies TAMOFEN (tamoxifen), ARIMIDEX® (anastrozole), FEMARA (letrozole), AROMASIN (exemestane) and MEGACE (megestrol) as comparable drug products, as they share the same indication and are used in the treatment of patients with hormonereceptor positive advanced or metastatic breast cancer.

7. In considering whether the introductory price of a category 3 new drug product appears excessive, one of the tests under the PMPRB’s pre-2010 Guidelines is whether it exceeds the prices of the comparable drug products in the same therapeutic class (Therapeutic Class Comparison (TCC) test). Based on the TCC test, the introductory maximum non-excessive (MNE) price was $161.1990 (Attachment 2).

8. A second test under the pre-2010 Guidelines is whether the Canadian price of the new drug product exceeds the prices of that drug in the countries listed in the Patented Medicines Regulations (Regulations). (see footnote 1) FASLODEX is sold in all seven comparator countries. Prices in these countries at the time of introduction ranged from $616.3043 (Italy) to $962.7268 (United States). The median international price was $692.2303. The Canadian price was $600.00, lower than the price of FASLODEX in all seven of the PMPRB reference countries.

9. The introductory MNE price ($161.1990) based on therapeutically comparable drugs in Canada is considerably lower (73.4% lower) than the lowest price in the comparator countries listed in the Regulations. Attachment 3 provides details of the international prices.

10. The price of FASLODEX in Canada has remained constant at $600.0000 since introduction in 2006.

11. FASLODEX is sold to a very small population of Canadian women to respond to their very specific needs. The market share of FASLODEX in Canada relative to the other hormonal therapies identified as therapeutic class comparators during the introductory period was very minimal (0.005%), and as units of sale have not increased measurably from the introductory period, its market share among the hormonal therapies has not grown appreciably during subsequent periods of sale (Attachment 4).

12. Section 85 of the Act identifies a comparison of the prices at which the medicine and other medicines in the same therapeutic class have been sold in countries other than Canada as one factor which the Board must take into account in its deliberation in contemplation of a remedial order.

13. It is within the Board’s discretion to ascribe the weight it deems appropriate to prices at which the medicine and other medicines in the same therapeutic class have been sold in countries other than Canada when considering the particular circumstances of any matter upon which it is adjudicating. The pre-2010 Guidelines do not provide for the International Therapeutic Class Comparison (ITCC) test, but the Board Guidelines which were implemented January 1, 2010 do in the context of an investigation for information purposes.

14. In light of the circumstances of this case, Board Staff has recommended that it is appropriate to rely on a ratio approach ITCC test. The ratio approach ITCC test was previously used in the HUMALOG (insulin lispro) and VIREAD (tenofovir disoproxil fumarate) cases in determining whether the prices were within the Guidelines.

15. Although MEGACE was the highest priced comparator in the domestic TCC test for FASLODEX, ARIMIDEX has the largest share of market sales and is also sold by AstraZeneca. As well, in two randomised clinical trials, ARIMIDEX has been compared to FASLODEX and determined to be clinically equivalent when used as second line hormonal therapy. Applying the median international ratio of FASLODEX to ARIMIDEX under the ITCC test to the price of ARIMIDEX in Canada would yield an introductory MNE price (now known as the maximum average potential price (MAPP)) of $521.2350 for FASLODEX (Attachment 5).

16. Board Staff and AstraZeneca are proposing that the ITCC test be used to set the introductory MNE price for FASLODEX at $521.2350, rather than using the TCC test result ($161.1990). On this basis, AstraZeneca and Board Staff have also agreed on a VCU (Attachment 1). Subject to the outcome of this Notice and Comment it is recommended that this VCU be accepted by the Vice-Chairperson.

C. Process for Submissions

17. All persons who wish to make representations in this matter shall file a written submission with the Board on or before September 17, 2010.

18. All submissions by the provincial and territorial Ministers of Health will be considered by the Board.

19. All submissions by other persons shall include a clear statement of the person’s interest in this matter, and shall state the reasons why the Board should consider the submission.

20. All submissions shall be filed with the Director, Board Secretariat at Box L40, 333 Laurier Avenue West, Suite 1400, Ottawa, Ontario K1P 1C1. Further information on the role and process of the Board may also be obtained from the Director, Board Secretariat.

21. Board Staff and AstraZeneca will be given the opportunity to make written submissions to the Board in response to any written submissions received within fifteen (15) days thereafter, no later than October 1, 2010.

22. The Vice-Chairperson will consider all submissions in determining whether to accept the proposed Voluntary Compliance Undertaking.

23. The Vice-Chairperson’s decision and all submissions will be posted on the PMPRB Web site.

Ottawa, June 11, 2010

D. Table of Contents

1. FASLODEX: Attachment 1 — Voluntary Compliance Undertaking

2. FASLODEX: Attachment 2 — Therapeutic Class Comparison

3. FASLODEX: Attachment 3 — International Price Comparison

4. FASLODEX: Attachment 4 — Market Shares of Faslodex and its Comparators

5. FASLODEX: Attachment 5 — International Therapeutic Class Comparison

Attachment 1 — Voluntary Compliance Undertaking

Voluntary Compliance Undertaking of AstraZeneca Canada Inc. to the Patented Medicine Prices Review Board

1.0 Product Summary

1.1 FASLODEX® (fulvestrant) is indicated for the hormonal treatment of locally advanced or metastatic breast cancer in post menopausal women, regardless of age, who have disease progression following prior endocrine therapy. It is supplied as a pre-filled syringe with a strength of 50 mg/mL and is administered at monthly intervals as a single 5 mL intramuscular injection.

1.2 Health Canada issued a Notice of Compliance (NOC) to AstraZeneca Canada Inc. (AstraZeneca) for FASLODEX on February 17, 2004 (DIN 02248624). FASLODEX was first sold in Canada on February 1, 2006.

1.3 Canadian Patent No. 2,351,004 pertaining to FASLODEX was granted to AstraZeneca AB, Sweden on February 18, 2003 and will expire on January 8, 2021. AstraZeneca is the patentee for the purposes of the Patented Medicines Prices Review Board (PMPRB).

2.0 Application of the Excessive Price Guidelines

2.1 The PMPRB’s Human Drug Advisory Panel (HDAP) recommended that FASLODEX be classified as a category 3 new drug product and identified oral hormonal treatments, namely, Tamofen (tamoxifen), ARIMIDEX® (anastrozole), Femara (letrozole), Aromasin (exemestane), and Megace (megestrol), as the most appropriate comparator drug products.

2.2 In accordance with the Board’s Excessive Price Guidelines (Guidelines), a Therapeutic Class Comparison (TCC) test and an International Price Comparison (IPC) test were conducted. The result of the TCC test indicated that the introductory price of $600.00 appeared to exceed the Guidelines as it was above the maximum non-excessive (MNE) price of $161.1990. The result of the IPC test indicated that the Canadian price was lower than the corresponding prices of FASLODEX in all seven of the PMPRB reference countries outlined in the Regulations.

2.3 The price of FASLODEX in Canada has remained constant at $600.0000 since it was first sold in 2006.

2.4 The Board’s Notice and Comment dated June 11, 2010 provides the details for the rationale and background information surrounding the application of the ratio approach International Therapeutic Class Comparison (ITCC) test for FASLODEX.

2.5 ARIMIDEX (anastrozole) has the largest share of market sales, is sold by AstraZeneca in Canada and is sold in all seven of the PMPRB reference countries. Applying the median international ratio of FASLODEX to ARIMIDEX under the ITCC test to the price of ARIMIDEX in Canada would yield an introductory MNE price of $521.2350. Cumulative excess revenues calculated by Board Staff as having been received by AstraZeneca as a result of selling FASLODEX at a price above the MNE price were $405,030.29 as of December 31, 2009.

3.0 Position of the Patentee

3.1 This Voluntary Compliance Undertaking (VCU) constitutes no admission by AstraZeneca that the price in Canada of FASLODEX is now, or was at any time since the date of the first sale of the medicine, excessive for purposes of the Patent Act.

3.2 AstraZeneca will not be bound by the undertaking herein unless this VCU is accepted by the Board.

4.0 Terms of the Voluntary Compliance Undertaking

4.1 In order to comply with the Guidelines, AstraZeneca agrees to undertake the following:

4.1.1 To agree that the MNE prices of FASLODEX are as follows:

2006 — $521.2350
2007 — $532.1809
2008 — $544.6906
2009 — $546.7755
2010 — $558.7899

4.1.2 To reduce the price of FASLODEX within 30 days of the acceptance of this VCU so that it does not exceed the 2010 MNE price of $558.7899;

4.1.3 To offset the cumulative excess revenues received from February 2006 to December 31, 2009 by making a payment to Her Majesty in right of Canada in the amount of $405,030.29 within 30 days of the acceptance of the VCU;

4.1.4 To offset any excess revenues received during the period January 1, 2010 to the date of reduction of the price of FASLODEX as per 4.1.1 of this VCU by making a payment within 30 days of the filing of semi-annual price and sales data as required by the Patented Medicines Regulations in the amount of the excess revenues, as calculated by Board Staff, received as a result of selling FASLODEX at a price in excess of the 2010 MNE price set out in sub-paragraph 4.1.1 above;

4.1.5 Within 15 days of acceptance of this VCU, to provide notification to customers of the price reductions for FASLODEX and that this price reduction is the result of an undertaking to the PMPRB, to provide a reference to the PMPRB Web site for the complete text of the VCU, and to provide copies of such notifications to Board Staff;

4.1.6 To file evidence with Board Staff within 30 days of the acceptance of this VCU that the price of FASLODEX has been reduced in a manner consistent with the terms of this VCU; and

4.1.7 To ensure that the price of FASLODEX remains within the Guidelines in all future periods in which FASLODEX is under the PMPRB’s jurisdiction.

AstraZeneca Canada Inc. Signature: Original signed by Company Officer: Marion E. McCourt Position: President and CEO Date: June 11, 2010

Attachment 2 — Therapeutic Class Comparison

Therapeutic Class Comparison

Strength

Dosage Regime

Unit Price

Cost per 30 Day Treatment

Faslodex (fulvestrant)

250 mg/5 mL

1 vial every 30 days

600.00001

600.0000

Tamofen (tamoxifen)

20 mg

1 tab daily x30 days

0.35002

10.5000

Arimidex (anastrozole)

1 mg

1 tab daily x30 days

4.95002

148.5000

Femara (letrozole)

2.5 mg

1 tab daily x30 days

4.95002

148.5000

Aromasin (exemestane)

25 mg

1 tab daily x30 days

4.95002

148.5000

Megace (megestrol)

160 mg

1 tab daily x30 days

5.37332

161.1990

Megace (megestrol)

40 mg

4 tab daily x30 days

1.34302

161.1600

Notes:

1 Publicly available ex-factory price as per Patented Medicines Regulations
2 Ontario Drug Benefit Formulary 2005 & September 2006

Highest allowable unit price based on cost per treatment $161.1990 of Megace 160 mg

Attachment 3 — International Price Comparison

International Price Comparison
Faslodex (250 mg/5 mL Syringe)
International Prices1
January-June 2006
(Cdn $)4

Country

Price per 250 mg/5 mL Syringe

Canada

$600.0000

Germany

$693.6503

France

$692.2303

Italy

$616.3043

Sweden

$624.9171

Switzerland

$664.9642

UK

$737.3052

US2,3

$962.7268

Median

$692.2303

1 Sources for Prices:

Canada: Publicly available ex-factory price as per Patented Medicines Regulations Germany: Rote Liste, January 2006 France: Sempex, February 2006 Italy: L’informatore farmaceutico, June 2006 Sweden: Prislista, June 2006 Switzerland: Medwin website, January-June 2006 UK: Mims, June 2006 US: Federal Supply Schedule (FSS), January-June 2006 Thomson Micromedex Wholesale Acquisition Cost (WAC), April 2006

2 The methodology for deriving net backed-out price can be found in the study, “Verification of Foreign Patented Drug Prices 2000” available on the PMPRB Web site www.pmprb-cepmb.gc.ca under Other Publications; Study Series

3 For the US, there is no national drug formulary, nor regulated mark-ups. The Red Book publishes a Direct Price (DP); the Federal Supply Schedule (FSS) includes a drug formulary for purposes of several federal drug plans and represents the prices paid by the U.S. Government. Thomson Micromedex publishes a Wholesale Acquisition Cost (WAC). For purposes of this comparison, the U.S. price has been estimated by averaging the WAC and FSS

4 Exchange rates based on 36-months ending June 2006 as per PMPRB Compendium Schedule 3

Country

Exchange Rate

Canada

1.00000000

Germany

1.53510000

France

1.53510000

Italy

1.53510000

Sweden

0.16695556

Switzerland

0.99106389

UK

2.24159444

US

1.25196111

Attachment 4 — Market Shares of Faslodex and its Comparators

Market Shares of Faslodex and its Comparators

Introductory Period

January-June 2006 Period

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

300.0

$169,000.00

$563.3333

0.005%

Tamofen 20 mg/tab

270,000.0

$94,000.00

$0.3481

4.3%

Arimidex 1 mg/tab

3,447,000.0

$17,577,000.00

$5.0992

54.6%

Femara 2.5 mg/tab

1,878,000.0

$10,050,000.00

$5.3514

29.7%

Aromasin 25 mg/tab

687,000.0

$3,541,000.00

$5.1543

10.9%

Megace 160 mg/tab

36,000.0

$115,000.00

$3.1944

0.6%

Total

6,318,300.0

$31,546,000.00

$582.4809

100.0%

Note: IMS, June 2006

January-December 2006 Period

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

1,000.0

$647,000.00

$647.0000

0.007%

Tamofen 20 mg/tab

528,000.0

$186,000.00

$0.3523

3.9%

Arimidex 1 mg/tab

7,335,000.0

$37,416,000.00

$5.1010

54.6%

Femara 2.5 mg/tab

4,032,000.0

$21,623,000.00

$5.3628

30.0%

Aromasin 25 mg/tab

1,467,000.0

$7,585,000.00

$5.1704

10.9%

Megace 160 mg/tab

60,000.0

$6,990,000.00

$116.5000

0.4%

Total

13,423,000.0

$74,447,000.00

$779.4866

100.0%

Note: IMS, December 2006

Market Shares of Faslodex and its Comparators for the 2007 to 2009 Periods

2007

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

1,600.0

$984,000.00

$615.0000

0.011%

Tamofen 20 mg/tab

426,000.0

$153,000.00

$0.3592

2.8%

Arimidex 1 mg/tab

8,265,000.0

$42,213,000.00

$5.1074

54.3%

Femara 2.5 mg/tab

4,839,000.0

$26,169,000.00

$5.4079

31.8%

Aromasin 25 mg/tab

1,662,000.0

$8,582,000.00

$5.1637

10.9%

Megace 160 mg/tab

24,000.0

$131,000.00

$5.4583

0.2%

Total

15,217,600.0

$78,232,000.00

$636.4965

100.0%

Note: IMS, December 2007

2008

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

1,800.0

$1,098,000.00

$610.0000

0.011%

Tamofen 20 mg/tab

345,000.0

$124,000.00

$0.3594

2.2%

Arimidex 1 mg/tab

9,057,000.0

$46,393,000.00

$5.1223

57.2%

Femara 2.5 mg/tab

4,626,000.0

$31,202,000.00

$6.7449

29.2%

Aromasin 25 mg/tab

1,782,000.0

$9,194,000.00

$5.1594

11.3%

Megace 160 mg/tab

21,000.0

$139,000.00

$6.6190

0.1%

Total

15,832,800.0

$88,150,000.00

$634.0051

100.0%

Note: IMS, December 2008

2009(1)

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

800.0

$553,000.00

$691.2500

0.009%

Tamofen 20 mg/tab

147,000.0

$53,000.00

$0.3605

1.7%

Arimidex 1 mg/tab

4,587,000.0

$23,560,000.00

$5.1363

53.3%

Femara 2.5 mg/tab

2,997,000.0

$16,852,000.00

$5.6230

34.8%

Aromasin 25 mg/tab

873,000.0

$4,500,000.00

$5.1546

10.1%

Megace 160 mg/tab

-

-

-

-

Total

8,604,800.0

$45,518,000.00

$707.5244

100.0%

Notes: IMS, June 2009

Megace 160 mg was reported as having less than a 1000 units sold (-)

Megace 40 mg was not reported in IMS during any period

Market Shares of Faslodex and Arimidex

January-December 2007 Period

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

1,600.0

$984,000.00

$615.0000

0.02%

Arimidex 1 mg/tab

8,265,000.0

$42,213,000.00

$5.1074

99.98%

Total

8,266,600.0

$43,197,000.00

-

100.00%

January-December 2008 Period

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

1,800.0

$1,098,000.00

$610.0000

0.02%

Arimidex 1 mg/tab

9,057,000.0

$46,393,000.00

$5.1223

99.98%

Total

9,058,800.0

$47,491,000.00

-

100.00%

January-June 2009 Period

Units

Sales Revenue

Unit Price

% of Market Share

Faslodex 250 mg/5 mL syringe

800.0

$553,000.00

$691.2500

0.02%

Arimidex 1 mg/tab

4,587,000.0

$23,560,000.00

$5.1363

99.98%

Total

4,587,800.0

$24,113,000.00

-

100.00%

Note: IMS, (Dec 2007, Dec 2008 & Jun 2009) information was used for this table, which captures Hospital & Pharmacy markets only

Attachment 5 — International Therapeutic Class Comparison

International Therapeutic Class Comparison

Faslodex 250 mg/mL (DIN 02248624) Pricing Ratios in Canada and Other Countries1 Using Backed-Out2 International Formulary Prices for Faslodex and Comparators Cost per Treatment in Canadian Currency3 (Based on Date of First sale: February 2006)

Canada

France

Germany

Italy

Sweden

Faslodex 250 mg/mL

$600.0000

$633.5178

$694.8106

$605.6430

$638.8639

Arimidex 1 mg (30 mg)

$148.5000

$220.4640

$211.5360

$162.9060

$181.7700


Switzerland

UK

US

Equivalent Canadian Faslodex price

Faslodex 250 mg/mL

$694.4976

$709.1020

$1,028.5746

 

Arimidex 1 mg (30 mg)

$242.7780

$149.5620

$271.6770

$521.2350

Notes:

1 Sources for Prices:

All Faslodex and Arimidex prices taken from publicly available ex-factory price as per Patented Medicines Regulations. All comparators taken from public sources.

Canada: Ontario Drug Benefit Formulary, September 2006, Quebec February 2006

Germany: Rote Liste, January 2006

France: Sempex, February 2006

Italy: L’informatore farmaceutico, June 2006

Sweden: Prislista, June 2006

Switzerland: Medwin website, January-June 2006

UK: Mims, June 2006

US: Federal Supply Schedule (FSS), January-June 2006

Thomson Micromedex Wholesale Acquisition Cost (WAC), April 2006

2 The methodology for deriving net backed-out price can be found in the study, “Verification of Foreign Patented Drug Prices 2000” available on the PMPRB Web site www.pmprb-cepmb.gc.ca under Other Publications; Study Series

3 Exchange rates based on 36-months ending September 2005 as per PMPRB Compendium Schedule 3

September 2005 36-month Exchange Rates

Country

Exchange Rate

Canada

1.00000000

Germany

1.58379444

France

1.58379444

Italy

1.58379444

Sweden

0.17323056

Switzerland

1.03508056

UK

2.32690833

US

1.33759167

PUBLIC SERVICE COMMISSION

PUBLIC SERVICE EMPLOYMENT ACT

Permission granted

The Public Service Commission of Canada, pursuant to section 116 of the Public Service Employment Act, hereby gives notice that it has granted permission, pursuant to subsection 115(2) of the said Act, to Melanie Fay Baete, Fire Rescue Technician (FR-01), Canadian Forces Base Shilo, Department of National Defence, Shilo, Manitoba, to be a candidate, before and during the election period, for the position of Member of the Local Urban District for the Town of Holland, Rural Municipality of Victoria, Manitoba, in a municipal election to be held on October 27, 2010.

July 6, 2010

KATHY NAKAMURA
Director General
Political Activities Directorate

[29-1-o]


Footnote 1
France, Germany, Italy, Sweden, Switzerland, the United Kingdom and the United States



NOTICE:
The format of the electronic version of this issue of the Canada Gazette was modified in order to be compatible with extensible hypertext markup language (XHTML 1.0 Strict).